Koers Addex Therapeutics Ltd Xetra
Aandelen
APE
CH0029850754
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 1,2 mln. 1,36 mln. 1,24 mln. | Omzet 2025 * | 750K 848K 776K | Marktkapitalisatie | 6,13 mln. 6,94 mln. 6,34 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -4 mln. -4,52 mln. -4,14 mln. | Nettowinst (verlies) 2025 * | -3 mln. -3,39 mln. -3,1 mln. | EV/omzet 2024 * | 1,36 x |
Nettoliquiditeiten 2024 * | 4,5 mln. 5,09 mln. 4,65 mln. | Nettoschuld 2025 * | 710K 802K 734K | EV/omzet 2025 * | 9,13 x |
K/w-verhouding 2024 * |
-2,08
x | K/w-verhouding 2025 * |
-2,5
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 35,04% |
Recentste transcriptie over Addex Therapeutics Ltd
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Tim Dyer
FOU | Founder | 56 | 01-01-02 |
Lénaic Teyssédou
DFI | Director of Finance/CFO | 38 | 01-06-17 |
Vincent Lawton
CHM | Chairman | 75 | 16-04-09 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jake Nunn
BRD | Director/Board Member | 53 | 01-06-18 |
Tim Dyer
FOU | Founder | 56 | 01-01-02 |
Vincent Lawton
CHM | Chairman | 75 | 16-04-09 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+24,74% | 47,54 mld. | |
-0,47% | 41,96 mld. | |
+43,96% | 41,55 mld. | |
+25,40% | 30,36 mld. | |
+17,96% | 27,61 mld. | |
-4,47% | 28,7 mld. | |
+50,73% | 14,7 mld. | |
+42,56% | 13,51 mld. | |
+1,46% | 12,34 mld. |